Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVIM + Virtue SAB refers to the two lead product candidates from Orchestra BioMed: Atrioventricular Interval Modulation (AVIM) Therapy and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB). AVIM Therapy is a bioelectronic treatment delivered via a standard pacemaker, designed to achieve immediate and sustained blood pressure reduction in patients with hypertensive heart disease by modulating the atrioventricular interval. Virtue SAB is a first-of-its-kind, non-coated drug delivery angioplasty balloon system that delivers a proprietary extended-release liquid formulation of sirolimus (SirolimusEFR) directly into the vessel wall for the treatment of atherosclerotic artery disease, including coronary in-stent restenosis, small vessel disease, and peripheral artery disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AVIM + Virtue SAB.